Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e65bbe180834339727074e7c621776eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b20bf4e7acb6371d23d34aa573c85847 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1647 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y204-02001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74 |
filingDate |
2012-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2016-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_302339f8537b7815e2fa7f7d7ebc569c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d46ed101d5dcfe78e2797f6db99c9383 |
publicationDate |
2016-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2012219269-B2 |
titleOfInvention |
Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase prodrug |
abstract |
The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells. |
priorityDate |
2011-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |